Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 187 for “"Synthetic lethality"”.

  1. Targeting ALC1 for synthetic lethality in cancer

    … targeting DNA repair pathways and inducing synthetic lethality, leading to improved patient outcomes. However, their non-specific inhibition of PARP activity presents challenges such as drug resistance, undesirable toxicities, and disruption of crucial cellular housekeeping functions …

    lmu-germany Repository record for Targeting ALC1 for synthetic lethality in cancer (opens in a new tab)

  2. TARGETING EPHB6 SYNTHETIC LETHALITY IN BREAST CANCER

    … in cancer cells. One approach is based on the synthetic lethality concept, where lethality occurs only when inhibition of a gene partner to the loss-of-function alteration is inhibited. EphB6, a kinase-dead member of the Eph receptor tyrosine kinase family, has anti-malignant properties and is …

    sask Repository record for TARGETING EPHB6 SYNTHETIC LETHALITY IN BREAST CANCER (opens in a new tab)

  3. TARGETING P53 DEFICIENCY IN CANCER THROUGH SYNTHETIC LETHALITY

    … coupled with p53 deficiency, exhibits synthetic lethality, although the mechanism remains unclear. Our proposed mechanism explains the synergistic effect: ATR inhibition depletes RPA1, exposing single-stranded DNA at stalled forks susceptible to degradation by MRE11/EXO1 nucleases in …

    nus Repository record for TARGETING P53 DEFICIENCY IN CANCER THROUGH SYNTHETIC LETHALITY (opens in a new tab) Download file for TARGETING P53 DEFICIENCY IN CANCER THROUGH SYNTHETIC LETHALITY (opens in a new tab)

  4. IDENTIFYING AND EXPLOITING SYNTHETIC LETHALITY FOR CANCER THERAPEUTICS

    Synthetic Lethality (SL) is considered a promising approach for the development of personalized treatments. However, SL interactions in humans remain largely unknown and there is a need to discover more such pairs, especially those that are clinically actionable, and to develop tools that can …

    nus Repository record for IDENTIFYING AND EXPLOITING SYNTHETIC LETHALITY FOR CANCER THERAPEUTICS (opens in a new tab) Download file for IDENTIFYING AND EXPLOITING SYNTHETIC LETHALITY FOR CANCER THERAPEUTICS (opens in a new tab)

  5. Identifying Synthetic Lethality Targets in DDX41-mutated MDS/AML

    … in humans. To address this barrier, we pursued a synthetic lethality (SL) approach to identify therapeutic vulnerabilities unique to DDX41 deficient cells. Bioinformatic analyses highlighted WRN, a RecQ helicase crucial for DNA replication fidelity, as a promising SL partner. Consistent with this …

    sask Repository record for Identifying Synthetic Lethality Targets in DDX41-mutated MDS/AML (opens in a new tab)

  6. Selective Synthetic Lethality for p53-mutant Metastatic Breast Cancer

    For decades, multiple efforts have been put into developing therapeutic strategies to target p53, which is commonly mutated in Breast Carcinoma. Most of these studies have been largely unsuccessful until recent. Currently, in this work, we developed a novel therapeutic approach combining two FDA …

    buffalo Repository record for Selective Synthetic Lethality for p53-mutant Metastatic Breast Cancer (opens in a new tab)

  7. BRCA1 E3 ligase inhibitors induces synthetic lethality in CPT resistant cells

    Camptothecin and its analogues (CPTs) represent one of the most potent classes of anticancer drugs used to treat several solid tumors. CPTs bind topoisomerase I during the replication process and cause DNA damage that results in cell death. However, its effectiveness is limited to 13-30 percent of …

    bu Repository record for BRCA1 E3 ligase inhibitors induces synthetic lethality in CPT resistant cells (opens in a new tab)

  8. Synthetic lethality in NSCLC cells: Interrogating the therapeutic potential of ATM deficiency

    … polymerase inhibitors (PARPi) induced synthetic lethality in Ataxia telangiectasia mutated (ATM) deficient cells. My work extended these studies to non-small cell lung cancer (NSCLC). In vitro, ATM deficient NSCLC cell lines were investigated by assessing DNA damage-induced …

    calgary Repository record for Synthetic lethality in NSCLC cells: Interrogating the therapeutic potential of ATM deficiency (opens in a new tab)

  9. Synthetic lethality of flavonoids towards homologous recombination deficient cells through PARP inhibition

    … BRCA2-/- ) were used to assess the degree of synthetic lethality due to PARP inhibition. Colony formation and doubling time assays identified selective toxicity in DNA repair deficient cells for the flavonoids Kaempferol, Myricetin, Quercetin, Theaflavin and Epigallocatechin gallate. A Sister …

    colostate Repository record for Synthetic lethality of flavonoids towards homologous recombination deficient cells through PARP inhibition (opens in a new tab)

  10. Synthetic lethality and synthetic cytotoxicity strategies for selective killing of ATM deficient cells

    … kill ATM-deficient cells resulting in synthetic lethality (SL), or sensitize ATM-deficient cells to a sub-lethal dose of DNA damaging agent resulting in synthetic cytotoxicity (SC). The goal of this research is to use budding yeast as a model system to identify candidate SL or SC …

    ubc Repository record for Synthetic lethality and synthetic cytotoxicity strategies for selective killing of ATM deficient cells (opens in a new tab) Download PDF for Synthetic lethality and synthetic cytotoxicity strategies for selective killing of ATM deficient cells (opens in a new tab)

  11. Investigations on the nucleotide excision repair protein XPD as a target for synthetic lethality

    … novel strategies for tumor therapeutics like synthetic lethality concepts could provide advanced treatment success. Synthetic lethality is a therapeutic strategy in which the dysfunction of two gene products leads to cell death, whereas dysfunction of each single one has no such effect. …

    wurz-thes Repository record for Investigations on the nucleotide excision repair protein XPD as a target for synthetic lethality (opens in a new tab)

  12. Metabolic reprograming of cancer cells using riboflavin to induce synthetic lethality by caix inhibitors /

    Carbonic anhydrase IX (CAIX) is a transmembrane enzyme overexpressed in many solid tumours, where it supports cancer cell survival under hypoxic conditions by regulating pH homeostasis. While hypoxia is a well-established inducer of CAIX via HIF-1α, recent evidence suggests that CAIX expression can …

    vilnius Repository record for Metabolic reprograming of cancer cells using riboflavin to induce synthetic lethality by caix inhibitors / (opens in a new tab)

  13. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Cancers

    PARP inhibitors (PARPi) have been used to induce synthetic lethality in BRCA-deficient tumors in clinical trials with limited success due to the development of resistance to PARPi. BRCA-deficient cells are unable to repair DNA double strand breaks by the accurate homologous recombination repair …

    temple Repository record for Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Cancers (opens in a new tab)

  14. Identification and characterisation of suppressors of synthetic lethality resulting from loss of SETD2 and WEE1

    <p>Our lab has recently identified a conserved synthetic lethality between loss of SETD2-dependent H3K36 trimethylation and inhibition of WEE1 kinase (Pfister et al., 2015). In order to explore the possible mechanisms of resistance to WEE1 inhibitor-treatment in H3K36me3-deficient cells, a yeast …

    oxford Repository record for Identification and characterisation of suppressors of synthetic lethality resulting from loss of SETD2 and WEE1 (opens in a new tab)

  15. Synthetic Lethality of Cdk Inhibition and Doxorubicin In Triple-Negative Breast Cancer Requires P53 Inactivation

    … roscovitine prior to doxorubicin treatment is synthetic lethal explicitly in TNBC cells. Furthermore, this novel combination therapy is well tolerated and efficacious, significantly reducing tumor volume and increasing overall survival compared to single drug treatment arms in a pre-clinical …

    uthsc Repository record for Synthetic Lethality of Cdk Inhibition and Doxorubicin In Triple-Negative Breast Cancer Requires P53 Inactivation (opens in a new tab)

  16. Investigating The Synthetic Lethality Between PTEN Loss and PNKP Inhibition in Glioma and Sarcoma Models

    … fork stability. Building on prior evidence of synthetic lethality caused by combined losses of PTEN and PNKP activity, in this study I aimed to determine whether PNKP inhibition would selectively sensitize PTEN-deficient glioma and sarcoma cell lines, and whether such vulnerability could be …

    calgary Repository record for Investigating The Synthetic Lethality Between PTEN Loss and PNKP Inhibition in Glioma and Sarcoma Models (opens in a new tab)

  17. Investigation into the relationship between PARPs in DNA repair and synthetic lethality with homologous recombination deficiency

    … deficient tumour cells, through a mechanism of synthetic lethality. Which subset of PARPs is necessary to inhibit to achieve maximum efficacy of these agents has not been assessed. </p> <p>I use genome editing to generate cells disrupted for these PARPs in different combinations. Whilst loss of …

    oxford Repository record for Investigation into the relationship between PARPs in DNA repair and synthetic lethality with homologous recombination deficiency (opens in a new tab)

  18. Utilizing the IN4MER CRISPR/CAS12A Multiplex Knockout Platform To Investigate Synthetic Lethality in the Human Genome

    … to achieve in the clinic. The concept of synthetic lethality has gained traction as a promising opportunity to discover novel cancer-specific vulnerabilities and therapeutic targets. Unfortunately, initial technologies for combinatorial genetic perturbation in mammalian cells suffer from …

    uthsc Repository record for Utilizing the IN4MER CRISPR/CAS12A Multiplex Knockout Platform To Investigate Synthetic Lethality in the Human Genome (opens in a new tab)

  19. Induction of Synthetic Lethality In Mutant Kras Cells For Non-Small Cell Lung Cancers Chemoprevention and Therapy

    … of TRAIL and Smac mimetic induced the synthetic lethal reaction specifically in the mutant-KRAS cells but not in normal lung cells and wild-type KRAS lung cancer cells. Therefore, a synthetic lethal interaction among TRAIL, Smac mimetic and KRAS mutations could be used as an approach …

    uthsc Repository record for Induction of Synthetic Lethality In Mutant Kras Cells For Non-Small Cell Lung Cancers Chemoprevention and Therapy (opens in a new tab)

  20. Advancing Precision Medicine for STAG2-Mutated Ewing Sarcoma through the Investigation of Synthetic Lethality and Circulating Tumor DNA

    … screening approaches, and the concept of synthetic lethality (SL). This part centers around the manuscript Time-dependent synthetic lethality in STAG2-mutated Ewing sarcoma, in which I report the results of time-course CRISPR and drug screening in isogenic Ewing sarcoma models. This work …

    zurich Restricted access

Page 1 of 10